Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board of Directors

PETALUMA, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Russell ("Russ") Harrison to its board of directors, effective February 26, 2014.

"We are pleased to welcome Russ to our board," stated Jim Schutz, CEO of Oculus. "His extensive business background, including strong executive experience in strategic planning, will be a terrific resource as we re-focus our energy on increasing revenue growth and longer term planning."

Harrison is the founding principal of The Leadership Group, a firm specializing in strategic change and executive coaching for U.S. and international corporations. He began his business career with then-fledgling Electronic Data Systems. In the years after, Russ served as senior vice president at Bank of America, as chief information officer at McKesson and at SITA Telecommunications Holdings (a global communications firm in Paris), and as founding president of AMR Information Systems, an American Airlines information technology subsidiary. He has served in the role of chief executive officer for a number of publicly traded and private companies in both the information technology and medical device sectors.

Harrison received an MBA with honors from Saint Mary's College of California, and has served as president of the board of regents, and as chairman of the board of trustees at Saint Mary's. He earned his bachelor's degree in economics from the University of Southern California and also served as a captain in the United States Marine Corps.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 31 countries. The company's products are used to treat patients in surgical/advanced wound management, dermatology, women's health and animal health; addressing the unmet medical needs of these markets, while raising the standard of patient care and lowering overall healthcare costs.  The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "anticipates," "believes," "expects," and "intends," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, the uncertainties associated with an initial public offering of a separate public company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

High-resolution photo of Mr. Harrison available upon request.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com

Released February 27, 2014